5,8-二氢萘-1,4-二酮 | 6295-28-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5,8-二氢萘-1,4-二酮
• 英文名称: 5,8-dihydro-1,4-naphthoquinone
• 英文别名: 5,8-Dihydronaphthalene-1,4-dione
• CAS: 6295-28-9
• 化学式: C₁₀H₈O₂
• 分子量: 160.172
• InChiKey: APSZOJQDLQCBRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,8-二氢萘-1,4-二酮 反应 1.33h， 以2.5 g的产率得到1,4-二羟基萘
  参考文献：
  名称：

  Russkikh, V. V.; Chernenko, G. F.; Bukhtoyarova, A. D., Journal of Organic Chemistry USSR (English Translation), 1986, vol. 22, p. 498 - 503

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium nitrite 作用下， 生成 5,8-二氢萘-1,4-二酮
  参考文献：
  名称：

  Fieser et al., Journal of the American Chemical Society, 1948, vol. 70, p. 3177

  摘要：

  DOI：

文献信息

• Preparation process of naphthoquinone derivative and intermediate for
  申请人：Eisai Chemical Co., Ltd.

  公开号：US05412124A1

  公开（公告）日：1995-05-02

  Disclosed herein are a naphthoquinone derivative represented by the following formula: ##STR1## wherein R.sup.1 means a hydrogen atom or methyl group, R.sup.2 is a hydrogen atom or methyl group, n stands for 0 or an integer of 1-9, and a linkage is a single bond or double bond with the proviso that if n is an integer of 2-9, the linkages may be identical with or different optionally from each other, such as a vitamin K derivative; and a process for producing the naphthoquinone derivative at a high yield without forming any geometric isomer; as well as 1,4,4.sub.a,5,8,9.sub.a -hexahydro-4.sub.a .alpha.-alkenyl-1.alpha.,4.alpha.-methanoanthraquinone derivatives and 1,4,4.sub.a,5,8,9.sub.a -hexahydro-1.alpha.,4.alpha.-methanoanthraquinone derivatives which are useful as intermediates for the preparation of the naphthoquinone derivatives.

  本公开涉及一种萘醌衍生物，其化学式如下：##STR1## 其中，R.sup.1代表氢原子或甲基，R.sup.2代表氢原子或甲基，n表示0或1-9的整数，连接是单键或双键，但如果n是2-9的整数，则连接可以是相同的或不同的，例如维生素K衍生物；以及一种在高产率下制备萘醌衍生物且不形成任何几何异构体的方法；以及作为制备萘醌衍生物的中间体有用的1,4,4.sub.a,5,8,9.sub.a-六氢-4.sub.a .alpha.-烯基-1.alpha.,4.alpha.-甲基蒽醌衍生物和1,4,4.sub.a,5,8,9.sub.a-六氢-1.alpha.,4.alpha.-甲基蒽醌衍生物。
• Isoquinoline derivatives
  申请人：Glaxo Group Limited

  公开号：US04835158A1

  公开（公告）日：1989-05-30

  Pharmaceutical compositions for combatting cancer comprising a compound of formula (I) ##STR1## (wherein R.sup.1 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl group; R.sup.2 represents a hydrogen atom or a hydroxyl, C.sub.1-4 alkoxy or C.sub.2-4 alkanoyloxy group; R.sup.3 represents a hydrogen atom, or (when R.sup.2 is other than a hydrogen atom) optionally a hydroxyl, C.sub.1-4 alkoxy or C.sub.2-4 alkanoyloxy group, or R.sup.2 and R.sup.3 together represent a methylenedioxy group; R.sup.4 represents a hydrogen or halogen atom or a C.sub.1-3 alkyl group or a phenyl group optionally substituted by a halogen atom or a hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or C.sub.1-4 alkanoyloxy group; and the ring A represents a group of formula ##STR2## where R.sup.5 and R.sup.6 each represent a hydrogen atom or a hydroxyl, C.sub.1-4 alkoxy or C.sub.1-4 alkanoyloxy group, R.sup.7 and R.sup.8 each represents a hydrogen atom or a methyl group, and one of X, X.sup.1, X.sup.2 and X.sup.3 represents a nitrogen atom and the others represent --CH-- groups; with the proviso that where A represents a group of formula (i) at least one of R.sup.1 to R.sup.6 represents other than a hydrogen atom) together with at least one pharmaceutical carrier or excipient.

  用于对抗癌症的药物组合物，包括式（I）的化合物 其中R.sup.1代表氢原子或C.sub.1-4烷基、C.sub.2-4烯基或C.sub.2-4炔基；R.sup.2代表氢原子或羟基、C.sub.1-4烷氧基或C.sub.2-4酰氧基；R.sup.3代表氢原子，或（当R.sup.2不是氢原子时）可选地是羟基、C.sub.1-4烷氧基或C.sub.2-4酰氧基，或R.sup.2和R.sup.3一起代表亚甲二氧基基团；R.sup.4代表氢或卤原子或C.sub.1-3烷基或苯基，可选地被卤原子或羟基、C.sub.1-4烷基、C.sub.1-4烷氧基或C.sub.1-4酰氧基取代；环A代表式的一个基团 其中R.sup.5和R.sup.6各自代表氢原子或羟基、C.sub.1-4烷氧基或C.sub.1-4酰氧基，R.sup.7和R.sup.8各自代表氢原子或甲基，X、X.sup.1、X.sup.2和X.sup.3中的一个代表氮原子，其他代表-CH-基团；条件是当A代表式（i）的一个基团时，至少R.sup.1到R.sup.6中的一个代表非氢原子）以及至少一个药用载体或赋形剂。
• New Catalytic Reactions in the Presence of Mo-V-Phosphoric Heteropoly Acid Solutions
  作者：E. G. Zhizhina、M. V. Simonova、V. V. Russkikh、K. I. Matveev

  DOI：10.1007/s11167-005-0386-9

  日期：2005.5

  The possibility of performing new catalytic reactions in the presence of solutions of H x+3PMo12−x . VxO40 Mo-V-phosphoric heteropoly acids was examined.

  研究了在 H x+3PMo12-x .VxO40 Mo-V-磷酸杂多酸溶液中进行新催化反应的可能性进行了研究。
• Selective Electrochemical Recognition of the α-Naphthol Isomer and In Situ Immobilization of Naphthoquinones for Tunable Electrocatalysis
  作者：Puchakayala Swetha、Annamalai Senthil Kumar

  DOI：10.1002/asia.201201170

  日期：2013.5

  Fits like a glove: Separationless and selective electrochemical oxidation of the α‐naphthol (α‐NAP) isomer yields naphthoquinone species on the surface of multiwalled carbon nanotubes, which can further catalyze the electro‐oxidation of NADH and hydrazine at different potentials. The β‐NAP isomer failed to show any such electro‐oxidation.

  像手套一样适合：α-萘酚（α-NAP）异构体的不可分离和选择性的电化学氧化在多壁碳纳米管的表面产生萘醌类物质，可以进一步催化NADH和肼在不同电势下的电氧化。β‐NAP异构体未显示任何此类电氧化作用。
• Preparation and electrochemical properties of palladium(0) complexes coordinated by quinones and 1,5-cyclooctadiene
  作者：Mitsuo Hiramatsu、Katsuyuki Shiozaki、Tatsuo Fujinami、Shizuyoshi Sakai

  DOI：10.1016/0022-328x(83)80202-2

  日期：1983.4

  The complexes Pd(quinone)(COD) (COD = 1,5-cyclooctadiene) are prepared by a ligand substitution reaction of Pd2(DBA)3 (DBA = dibenzylideneacetone) in the presence of both quinone and COD. Palladium(0) complexes coordinated by quinones only are formed in the reaction in the absence of COD. The cyclic voltammetric behavior of Pd(quinone)(COD) has been studied. The reduction potentials for quinones shifted

  配合物Pd（醌）（COD）（COD = 1,5-环辛二烯）是在醌和COD均存在下通过Pd 2（DBA）3（DBA =二苄叉基丙酮）的配体取代反应制备的。在没有COD的情况下，反应中仅生成由醌配位的钯（0）配合物。研究了Pd（醌）（COD）的循环伏安行为。与钯（0）配位时，醌的还原电势向负值移动。Pd（醌）（COD）中中心钯（0）的氧化电势取决于游离醌的吸电子能力，并按以下系列计算：醌= p-苯醌＜5，8-二氢-1，4-萘醌〜1，4-萘醌＜对苯二酚。Pd（醌）（COD）的氧化势在改变醌为配体时的变化与Pd（醌）（三苯基膦）2的变化相反。